In patients with chronic kidney disease, SGLT2 inhibitors (dapagliflozin end empagliflozin) were found to exert significant renoprotective actions and are now considered the mainstay of prevention and treatment in patients with or without diabetes [18,19]. Here, SLC5A2 is linked to diabetes mellitus.